Cincinnati, OHNCT07203001Now EnrollingIRB Ready

Still´s Disease Clinical Trial in Cincinnati, OH

Access cutting-edge still´s disease treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Cincinnati location

Preparing your pre-screening questions…

Expert Care in Cincinnati

Access still´s disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related still´s disease treatment provided free

Apply for This Cincinnati Location

Check if you qualify for this still´s disease clinical trial in Cincinnati, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cincinnati

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cincinnati site if eligible
  4. 4Begin participation

About This Still´s Disease Study in Cincinnati

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Age ≥ 1 with a diagnosis of Still's Disease
Active diseases defined as:
CRP or ferritin levels greater than ULN, and any of:
Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or
Rash attributed to Still's Disease activity or
Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or
Serositis or
Macrophage activation syndrome activity as defined by ferritin levels and at least one of: platelet count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator
Intolerance or inadequate response to available biologic therapy

Exclusion Criteria

Patients out of weight range
Ongoing or previous treatment with immunomodulatory drugs
A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
Glucocorticoid dose exceeding a set limit
Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy
Still's disease patients with evidence of macrophage activation syndrome are permitted in the study
Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study
History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and/or symptoms and signs of clinically significant active bacterial, fungal or viral infections
Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose
History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients
Pregnant or breastfeeding women
Women of child-bearing potential who do not agree to comply with required contraceptive use Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cincinnati?

Yes, this clinical trial (NCT07203001) has an active research site in Cincinnati, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Still´s Disease Treatment Options in Cincinnati, OH

If you're searching for still´s disease treatment options in Cincinnati, OH, this clinical trial (NCT07203001) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced still´s disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all still´s disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Cincinnati, OH

See all ankylosing spondylitis clinical trials recruiting in Cincinnati — not just this study.

Browse Ankylosing Spondylitis Trials in Cincinnati →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsAll Conditions →

Ready to Join in Cincinnati?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cincinnati, OH